Yahoo Web Search

Search results

1. • • As of the time of this writing, Moderna has fallen over 50% from its 52-week in August 2021, equating to more than $98 billion of market capitalization being erased. At roughly nine times its trailing-12-month sales and a healthy profitability and cash profile, Moderna looks like a good buy going into 2022.
     www.fool.com/investing/2022/01/05/is-now-a-good-time-to-buy-moderna-stock/

     Is Now a Good Time to Buy Moderna Stock? | The Motley Fool

2. People also ask

   Is Moderna a good buy in 2022?

   • At roughly nine times its trailing-12-month sales and a healthy profitability and cash profile, Moderna looks like a good buy going into 2022 . Adam Spatacco does not own shares of any of the companies mentioned. The Motley Fool recommends Moderna Inc.

   Is Now a Good Time to Buy Moderna Stock? | The Motley Fool

   www.fool.com/investing/2022/01/05/is-now-a-good-time-to-buy-moderna-stock/

   See all results for this question

   Is now a good time to buy Moderna stock?

   • Is Now a Good Time to Buy Moderna Stock? The company will benefit if vaccination and booster rates increase. Now may be a good time to assess the stock as it hovers in between its 52-week range. You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services.

   Is Now a Good Time to Buy Moderna Stock? | The Motley Fool

   www.fool.com/investing/2022/01/05/is-now-a-good-time-to-buy-moderna-stock/

   See all results for this question

   How much money will Moderna make in 2022?

   • The figure represents a massive 2,191% jump from 2020. Moderna is expecting another good year, with $21bn in revenue forecast for 2022. However, demand for its key vaccine is certainly slowing. There were only $2.5bn of deals between January and March – which equates to around $830m a month.

   Is it time to buy Moderna shares? | The Motley Fool UK

   www.fool.co.uk/2022/06/13/is-it-time-to-buy-moderna-shares/

   See all results for this question

   How much money does Moderna make a year?

   • Moderna is expecting another good year, with $21bn in revenue forecast for 2022. However, demand for its key vaccine is certainly slowing. There were only $2.5bn of deals between January and March – which equates to around $830m a month. That’s slower than the previous rate of sales.

   Is it time to buy Moderna shares? | The Motley Fool UK

   www.fool.co.uk/2022/06/13/is-it-time-to-buy-moderna-shares/

   See all results for this question

   Will Moderna return to sales growth next year?

   • Primarily because of the huge opportunity for mResvia, Moderna expects to return to sales growth next year. And there could be more to come -- much more. The company has already announced positive results from a late-stage study of its influenza vaccine mRNA-1010.

   Why Moderna Stock Is a No-Brainer Buy Right Now - Yahoo Finance

   finance.yahoo.com/news/why-moderna-stock-no-brainer-095000828.html

   See all results for this question

   What's happening with Moderna stock?

   • Moderna stock (NASDAQ: MRNA) has rallied by about 13% over the last week (five trading days) and currently trades at about $417 per share. In contrast, the S&P 500 is up by just about 0.5% over the same period. There have been multiple positive developments for Moderna stock over the last few days.

   Moderna Stock Gains On More Good News, But Is It A Buy

   www.nasdaq.com/articles/moderna-stock-gains-on-more-good-news-but-is-it-a-buy-2021-09-09

   See all results for this question

3. www.fool.com › investing › 2021/12/21Moderna Stock: Buy, Sell, or Hold in 2022? | The Motley Fool

   www.fool.com › investing › 2021/12/21

   • Cached

   Dec 21, 2021 · Should you buy, hold, or sell Moderna shares in 2022? Overall, I vote for buying or holding -- that's because there's so much more ahead for this innovative company.

4. www.fool.com › investing › 2022/12/15Is Moderna a Good Stock to Buy Right Now? | The Motley Fool

   www.fool.com › investing › 2022/12/15

   • Cached

   Dec 15, 2022 · Is Moderna a Good Stock to Buy Right Now? By Cory Renauer – Dec 15, 2022 at 5:19AM. Key Points. Moderna's stock price recently jumped in response to positive results from a cancer trial....

   • Author: Cory Renauer

5. www.fool.com › investing › 2022/01/05Is Now a Good Time to Buy Moderna Stock? | The Motley Fool

   www.fool.com › investing › 2022/01/05

   • Cached

   Jan 5, 2022 · At roughly nine times its trailing-12-month sales and a healthy profitability and cash profile, Moderna looks like a good buy going into 2022.

6. www.fool.co.uk › 2022/06/13 › is-it-time-to-buyIs it time to buy Moderna shares? | The Motley Fool UK

   www.fool.co.uk › 2022/06/13 › is-it-time-to-buy

   • Cached

   Jun 13, 2022 · Moderna is expecting another good year, with $21bn in revenue forecast for 2022. However, demand for its key vaccine is certainly slowing. There were only $2.5bn of deals between January and...

7. www.morningstar.com › stocks › after-earnings-bigAfter Earnings and a Big Selloff, Is Moderna Stock a Buy?

   www.morningstar.com › stocks › after-earnings-big

   • Cached

   Aug 7, 2024 · We’re maintaining our $227 fair value estimate for Moderna despite disappointing management commentary surrounding the firm’s competitiveness in the upcoming covid and RSV vaccination season ...

8. finance.yahoo.com › news › why-moderna-stock-no-bWhy Moderna Stock Is a No-Brainer Buy Right Now - Yahoo Finance

   finance.yahoo.com › news › why-moderna-stock-no-b

   • Cached

   Jun 10, 2024 · In 2022, the biotech company generated sales of nearly $18.9 billion, but it expects revenue of only $4 billion this year. The real story for Moderna is much better than that steep sales...

9. www.nasdaq.com › articles › moderna-stock-gains-onModerna Stock Gains On More Good News, But Is It A Buy?

   www.nasdaq.com › articles › moderna-stock-gains-on

   • Cached

   Sep 9, 2021 · So is Moderna stock a buy at current levels of around $417 per share? The stock now trades at just about 14x projected 2021 earnings, as the near-term demand picture has improved, with analysts...